Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea

Sookyung Lim, Xiaoling Li, Olga Syrkina, Marion Fournier, Sookyung Lim, Xiaoling Li, Olga Syrkina, Marion Fournier

Abstract

Introduction: In 2017, a quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra®, Sanofi) was licensed in South Korea for active immunization against influenza A and influenza B viruses in individuals aged 3 years or older, which was subsequently extended to individuals aged 6 months or older in 2018. Post-marketing surveillance trials are mandatory in South Korea to retain drug licensure. Here, we assessed the safety of QIV in routine clinical practice in South Korea.

Methods: This was an open, multicenter, observational, active safety surveillance study conducted between 20 June 2017 and 19 June 2021 at 10 study sites in South Korea in individuals aged 3 years or older who received a single dose of QIV during a routine healthcare visit. The participants or their legally acceptable representatives were instructed to record any adverse reactions (solicited events) and unsolicited non-serious adverse events (AE) in diary cards, and notify study investigators in case of serious adverse events (SAE).

Results: Overall, 663 participants were included in this study. There were no AEs leading to study termination, and no SAEs reported. Injection site pain (278 [41.9%]) was the most frequent solicited injection site reaction, with myalgia (250 [37.7%]) and malaise (236 [35.6%]) the most frequent solicited systemic reactions. Grade 3 solicited injection site and systemic reactions were reported by 8 (1.2%) and 13 (2.0%) participants, respectively; most participants with solicited reactions recovered without the need for further action. Overall, 39 (5.9%) participants experienced 49 unsolicited non-serious AEs with the most frequently reported being nasopharyngitis (19 [2.9%]). Grade 3 unsolicited non-serious adverse events were reported in 1 (0.2%) participant. None of the unsolicited non-serious AEs were considered to be related to QIV.

Conclusion: This post-marketing surveillance study confirms that QIV is well tolerated and has an acceptable safety profile in routine practice in South Korea. No unexpected safety concerns were identified.

Trial registration: ClinicalTrials.gov identifier NCT05406180.

Keywords: Influenza; Post-marketing surveillance study; Quadrivalent inactivated split-virion influenza vaccine; Safety; South Korea; Vaxigrip Tetra.

© 2022. The Author(s).

References

    1. Hong K, Sohn S, Chun BC. Estimating Influenza-associated Mortality in Korea: the 2009–2016 Seasons. J Prev Med Public Health. 2019;52(5):308–315. doi: 10.3961/jpmph.19.156.
    1. Chungmin P, Gyehee L, Hyengil C, Jeongsuk S, Donghan L. Estimation of excess mortality associated with influenzas in Korea. Cheongju: Korea Disease Control and Prevention Agency (KDCA); 2021. p. 1157–61.
    1. Park M, Wu P, Goldstein E, Kim WJ, Cowling BJ. Influenza-associated excess mortality in South Korea. Am J Prev Med. 2016;50(4):e111–e119. doi: 10.1016/j.amepre.2015.09.028.
    1. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167–182. doi: 10.1038/nrd4529.
    1. Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018;15(1):17. doi: 10.1186/s12985-017-0918-y.
    1. WHO. Influenza. 2022. .
    1. Cozza V, Campbell H, Chang HH, et al. Global seasonal influenza mortality estimates: a comparison of 3 different approaches. Am J Epidemiol. 2021;190(5):718–727. doi: 10.1093/aje/kwaa196.
    1. Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39(Suppl 1):A6–A14. doi: 10.1016/j.vaccine.2020.09.048.
    1. Swets MC, Russell CD, Harrison EN, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463–1464. doi: 10.1016/S0140-6736(22)00383-X.
    1. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020;324(13):1342–1343. doi: 10.1001/jama.2020.14661.
    1. CDC. People at higher risk of flu complications. Atlanta: Centers for Disease Control and Prevention (CDC); 2021. .
    1. CDC. Similarities and differences between flu and COVID-19. Atlanta: Centers for Disease Control and Prevention (CDC); 2022. .
    1. WHO. Coronavirus disease (COVID-19) pandemic. Coronavirus disease (COVID-19); 2022. .
    1. Ren SY, et al. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. 2022;10(1):1–11. doi: 10.12998/wjcc.v10.i1.1.
    1. ECDC. Clinical characteristics of COVID-19. Stockholm: European Centre for Disease Prevention and Control; 2021.
    1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z.
    1. Gresset-Bourgeois V, Leventhal PS, Pepin S, et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra) Expert Rev Vaccines. 2018;17(1):1–11. doi: 10.1080/14760584.2018.1407650.
    1. Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Hum Vaccines Immunother. 2018;14(3):587–592. doi: 10.1080/21645515.2017.1381808.
    1. MFDS. Standard for re-examination of new drugs. Cheongju: Korean Ministry of Food and Drug Safety; 2020.
    1. Thiem VD, Chabanon A-L, Fournier M, et al. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older. Hum Vaccines Immunother. 2021;17(3):690–693. doi: 10.1080/21645515.2020.1795477.
    1. Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485–2492. doi: 10.1016/j.vaccine.2015.03.065.
    1. Pepin S, Szymanski H, Kobashi IAR, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: a phase III randomized controlled study. Hum Vaccines Immunother. 2016;12(12):3072–3078. doi: 10.1080/21645515.2016.1212143.
    1. Serradell L, Wagué S, Moureau A, Nissilä M, Chabanon A-L. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season. Hum Vaccines Immunother. 2021;17(4):1205–1210. doi: 10.1080/21645515.2020.1804247.
    1. Chabanon AL, Wague S, Moureau A, Nissila M, Serradell L. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season. BMC Public Health. 2021;21(1):358. doi: 10.1186/s12889-021-10378-8.
    1. Gandhi-Banga S, Chabanon A-L, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccines Immunother. 2019;15(9):2154–2158. doi: 10.1080/21645515.2019.1581538.
    1. Montomoli E, Torelli A, Manini I, Gianchecchi E. Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine Vaxigrip Tetra: preliminary results in children >/= 6 months and older adults. Vaccines (Basel) 2018;6(1):14. doi: 10.3390/vaccines6010014.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner